Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease : attrition rate and evolution of disease activity.

This study is based on the results from a Belgian expanded access program in which patients with active refractory and erosive rheumatoid arthritis (RA) were treated with intravenous infusions of infliximab in combination with methotrexate. The objectives of this study were to evaluate the continuation rate of infliximab and its clinical effect over a 7-year period and to document the reasons for discontinuation.